

CARDIO3 BIOSCIENCES TO ADDRESS AMERICAN INSTITUTIONAL INVESTORS IN JANUARY AT J.P. MORGAN HEALTHCARE CONFERENCE

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the development of regenerative therapies, announces its participation to the **33rd edition of the annual J.P. Morgan Healthcare Conference** which will be held from 12 to 16 January 2015 in San Francisco.

The J.P. Morgan Healthcare conference is the largest and most informative healthcare investment conference. This conference attracts a broad range of US-based analysts and institutional investors.

Cardio3 BioSciences will meet with potential investors and explain to them its on-going development programs and strategic vision for the future.

Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: *"2014 was rich in events for our company. We made significant progress in the European Phase III clinical trial of C-Cure® and our strategic development was strengthened by an enlarged collaboration with Mayo Clinic and the acquisition of CorQuest Inc. The J.P. Morgan Healthcare Conference is an excellent opportunity to present Cardio3 BioSciences' potential and strategic vision to new investors in view of increasing the visibility and the awareness of our Company towards large institutional investors."*

*** END ***

For more information, please contact:

Cardio3 BioSciences

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

www.c3bs.com

Tel. : +32 10 39 41 00

jgrade@c3bs.com

For Europe: Citigate Dewe Rogerson

Chris Gardner

Tel : +44 (0) 207 638 9571

Chris.Gardner@citigatedr.co.uk

For the U.S: Rx Communications Group

Eric Goldman

Tel: +1 917 322 2563

egoldman@RxIR.com

To subscribe to Cardio3 BioSciences' newsletter, visit www.c3bs.com.

 Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

[#JPMorgan](https://twitter.com/JPMorgan) [#Healthcare Conference](https://twitter.com/HealthcareConference)

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of unmet medical needs. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

15 DECEMBER 2014

3PM CET

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath_{ez}[®], the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath_{ez}, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath_{ez} logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.